Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids.
Accumulation of carbonyl derivatives of proteins (protein carbonyl) is taken as a biomarker of oxidative protein damage in aging and in various diseases. We detected protein carbonyls in situ in human diabetic arteriosclerotic tissues and characterized the formation of protein carbonyls. Protein carbonyls were identified in the thickened intima of arterial walls and co-localized with protein adducts formed by carbonyl amine chemistry between protein and carbonyl compounds derived from autoxidation of carbohydrates, lipids, and ascorbate, i.e. advanced glycation end products or glycoxidation products, such as carboxymethyllysine (CML) and pentosidine, and lipoxidation products, such as malondialdehyde (MDA) and 4-hydroxy-nonenal (HNE). In vitro incubation of proteins with ascorbic acid accelerated the production of protein carbonyls as well as CML and pentosidine, and incubation with arachidonate accelerated the production of protein carbonyls as well as CML, MDA, and HNE. By contrast, incubation of proteins with glucose resulted in the production of CML and pentosidine, but not protein carbonyls. Schiff base inhibitors, (+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylace tanilide and aminoguanidine, inhibited the production of protein carbonyls after incubation with ascorbate and arachidonate. The present study suggests that ascorbate and polyunsaturated fatty acids, but not glucose, represent potential sources of protein carbonyls, and that both the glycoxidation and lipoxidation reactions contribute to protein carbonyl formation in aging and various diseases.
Miyata
T
T
Institute of Medical Sciences and Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan. t-miyata@is.icc.u-tokai.ac.jp
Inagi
R
R
Asahi
K
K
Yamada
Y
Y
Horie
K
K
Sakai
H
H
Uchida
K
K
Kurokawa
K
K
D016718:Arachidonic Acid / Q000494:pharmacology; D001120:Arginine / Q000031:analogs & derivatives / Q000032:analysis; D001161:Arteriosclerosis / Q000378:metabolism*; D001205:Ascorbic Acid / Q000494:pharmacology; D003925:Diabetic Angiopathies / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006031:Glycosylation; D006801:Humans; D015227:Lipid Peroxidation; D008074:Lipoproteins / Q000378:metabolism; D008239:Lysine / Q000031:analogs & derivatives / Q000032:analysis; D008315:Malondialdehyde / Q000032:analysis; D010084:Oxidation-Reduction; D018384:Oxidative Stress
D017127:Glycation End Products, Advanced; D008074:Lipoproteins; D016718:Arachidonic Acid; D008315:Malondialdehyde; D001120:Arginine; C062187:pentosidine; D005947:Glucose; D008239:Lysine; D001205:Ascorbic Acid